U.S., Dec. 16 -- ClinicalTrials.gov registry received information related to the study (NCT07281677) titled 'Immunogenicity and Safety of Sequential 2vHPV-9vHPV Vaccination in Girls Aged 9-14 Years' on Dec. 01.
Brief Summary: This study aims to assess the immunogenicity and safety of a sequential 2vhpv to 9vhpv immunization schedule in girls aged 9-14 years
Study Start Date: Dec. 20
Study Type: INTERVENTIONAL
Condition:
HPV Infection
Intervention:
BIOLOGICAL: bivalent HPV vaccine
Bivalent HPV vaccine produced by Shanghai Zerun Biotechnology Co.,Ltd. or Wantai BioPharm.
BIOLOGICAL: 9-valent HPV vaccine
9-valent HPV vaccine is produced by Wantai BioPharm or Merck Sharp & Dohme LLC.
Recruitment Status: RECRUITING
Sponsor: Zhejiang ...